Global Contraceptive Devices Market Set To Grow To $18.7bn By 2022

03 August 2018
Pharma

Visiongain has launched a new pharma report Contraceptive Devices Market Report : Male Condoms, Female Condoms, Diaphragms, Sponges, Vaginal Rings, Subdermal/Contraceptive Implants, Intra-uterine Devices (IUDs), Copper IUD, Hormonal IUD
The evolution of contraceptive devices has opened a new outlook in the healthcare industry. Growth rate exhibited by the contraceptive devices market despite the shortages and lack of awareness among the population in various countries, confirms the positive growth prospects going ahead. The contraceptive devices market is highly competitive and has reached maturity resulting in single digit growth rates of prominent devices such as condoms, diaphragms, vaginal rings, sponges, etc.

The lead analyst of the report commented “The global contraceptive devices market is expected to experience a significant growth over the forecast period. The main drivers for the growth include rapid growth in population, development of technologically advanced contraceptive devices, huge burden of sexually transmitted diseases and HIV, increasing adoption of contraceptive devices and supportive government authorities.
The rising prevalence of sexually transmitted diseases (STDs) is increasing the need of more innovative products in the contraceptive devices market. At present, condoms are the only contraceptive devices that prevent from the risk of sexually transmitted infections & HIV therefore; manufacturers across the globe are enormously investing in R&D to come up with a product that would be reminiscent of contraceptive condoms in the prevention of sexually transmitted infections & HIV along with unintended pregnancies and birth control.”

Leading companies featured in the report include Bayer AG, Reckitt Benckiser Group plc
Merck Sharp & Dohme Corp., Church & Dwight Co., Inc., Teva Pharmaceutical Industries, Ltd.
Allergan plc, Ansell Limited (Now Humanwell), The Female Health Company (a division of VERU Inc.), Karex Industries, Mayer Laboratories, Kessel Medintim GmbH, Okamato Industries, Inc., Agile Therapeutics, Inc., Eurogine S.L.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021

Read

Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021

Read

Visiongain Publishes Aptamer Technologies Market Report 2021-2031

Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.

29 April 2021

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031

Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.

29 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever